KalVista Pharmaceuticals (NASDAQ:KALV) versus Crinetics Pharmaceuticals (NASDAQ:CRNX) Financial Survey

KalVista Pharmaceuticals (NASDAQ:KALV) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Volatility and Risk

KalVista Pharmaceuticals has a beta of -0.15, indicating that its share price is 115% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500.

Earnings and Valuation

This table compares KalVista Pharmaceuticals and Crinetics Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	N/A	N/A	-$183.44 million	($3.94)	-2.82
Crinetics Pharmaceuticals	$1.04 million	3,764.48	-$298.41 million	($4.11)	-10.11

KalVista Pharmaceuticals has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 4.3% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares KalVista Pharmaceuticals and Crinetics Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-195.62%	-89.96%
Crinetics Pharmaceuticals	N/A	-32.28%	-29.45%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for KalVista Pharmaceuticals and Crinetics Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	1	0	8	1	2.90
Crinetics Pharmaceuticals	1	2	11	0	2.71

KalVista Pharmaceuticals presently has a consensus price target of $26.43, suggesting a potential upside of 138.10%. Crinetics Pharmaceuticals has a consensus price target of $74.45, suggesting a potential upside of 79.11%. Given KalVista Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe KalVista Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

Summary

Crinetics Pharmaceuticals beats KalVista Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.